Dr. Benatti has over 30 years of experience in the pharmaceutical and biotechnology industries. He serves as the Chief Executive Officer and a Director of EryDel S.p.A., a private biotechnology company focused on rare diseases. Prior to EryDel, Dr. Benatti was Co-founder and CEO of Newron Pharmaceuticals S.p.A. Under his leadership, Newron developed a pipeline of innovative therapies including Xadago, approved worldwide for the treatment of Parkinson's Disease. Previously, Dr. Benatti held research and development positions at Pharmacia & Upjohn and its predecessor companies. Dr. Benatti has authored several scientific publications and holds a number of patents. He currently serves as a director of Intercept Pharmaceuticals, Newron Pharmaceuticals S.p.A. and Metis Precision Medicine. Dr. Benatti also serves as chairman of Italian Angels for Biotech, a member of the Advisory Board of the Sofinnova Telethon Fund, and as a member of the Development and of the Strategic Advisory Boards of Zambon S.p.A. Dr. Benatti graduated and performed post-doctoral work at the Milano Genetics Institute.

Samuel Broder, MD has spent a lifetime at the forefront of science and medicine in many diverse arenas. He is the former Director of the National Cancer Institute (NCI) where he oversaw the development of numerous anti-cancer therapeutic agents. Dr. Broder also helped launch a number of large-scale clinical trials related to the prevention, diagnosis, and treatment of cancer, and he inaugurated the highly successful Specialized Program of Research Excellence (SPORE). Furthermore, during the 1980s, his laboratory was responsible for developing the first 3 agents approved by FDA specifically to treat the AIDS virus (Retrovir® (AZT), Videx® (ddI), and HIVID® (ddC). He joined the Celera Corporation at its founding in 1998, as the Executive VP for Medical Affairs and Chief Medical Officer, and there he helped advance the human genome project. His most recent executive position was as SVP, Health Sector, Intrexon Corp, with responsibilities for gene therapy and synthetic biology. He is the author or co-author of over 340 scientific publications, and is an inventor on many patents. He has received numerous awards related to his research in cancer and AIDS. He was elected to the National Academy of Medicine in 1993. He graduated from the University of Michigan Medical School in Ann Arbor in 1970, did an internship and residency in Internal Medicine at Stanford University in Palo Alto, and then did subspecialty training in medical oncology at the National Cancer Institute in Bethesda, Maryland.

Dr. Leoni is a scientific serial entrepreneur and founder of six biomedical companies in the US and in Europe with an extensive network within academic, financial and industrial biotech and medtech industries. Mr. Leoni is a co-founder of Gain Therapeutics and currently serves as Chairman of the Board of Industrie Biomediche Insubri SA, a board member of Artificaly SA, and a managing partner of TiVenture SA, investing in biomedical, medical devices, industrial high-tech, digital health and other high potential companies. Dr. Leoni received his Ph.D. in biochemistry from University of Lausanne and completed his post-doctoral fellowship at the University of California San Diego, where he served as Assistant Professor in the department of Medicine, Division of Hematology Oncology.

Dr. Michel Vellard, Ph.D., has served as a scientific advisor to Gain since November 2018. Dr. Vellard has more than 25 years of experience in molecular and cellular biology. He currently serves as chief scientific officer for Home Biosciences. He has also developed his career as co-founder and chief scientific officer at Audacity Therapeutics, vice president of research at Ultragenyx Pharmaceuticals and head of lysosomal biology, previously director of research and development, principal scientist at BioMarin where he was involved with most of the products developed there, and managed several programs including TFEB (collaboration with TIGEM/A. Ballabio), Duchenne muscular dystrophy (Phase I) and particularly an enzyme replacement therapy (ERT) for Morquio syndrome, the latest (VIMIZIM) has been approved in 2014. As a postdoctoral fellow, Dr. Vellard worked on rare diseases specifically researching the gene responsible for lysosomal disease cystinosis. Dr. Vellard studied extensively with Emil Kakkis at Harbor, specifically on lysosomal diseases and ERT. Dr. Vellard holds multiples patents and has authored and co-authored many research publications. Dr. Vellard received his B.S. in Natural and Life Sciences and M.S. in Molecular and Cellular Genetics from the University of Lyon I. He received his Ph.D. in Virology Pasteur from University of Paris VI, VII, XI.